Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits

  1. Diego Acosta-Alvear
  2. Min Y Cho
  3. Thomas Wild
  4. Tonia J Buchholz
  5. Alana G Lerner
  6. Olga Simakova
  7. Jamie Hahn
  8. Neha Korde
  9. Ola Landgren
  10. Irina Maric
  11. Chunaram Choudhary
  12. Peter Walter
  13. Jonathan S Weissman  Is a corresponding author
  14. Martin Kampmann
  1. University of California, San Francisco, United States
  2. University of Copenhagen, Denmark
  3. Onyx Pharmaceuticals, Inc. an Amgen subsidiary, United States
  4. National Institutes of Health, United States
  5. National Cancer Institute, United States

Abstract

Hallmarks of cancer, including rapid growth and aneuploidy, can result in non-oncogene addiction to the proteostasis network that can be exploited clinically. The defining example is the exquisite sensitivity of multiple myeloma (MM) to 20S proteasome inhibitors, such as carfilzomib. However, MM patients invariably acquire resistance to these drugs. Using a next-generation shRNA platform, we found that proteostasis factors, including chaperones and stress-response regulators, controlled the response to carfilzomib. Paradoxically, 19S proteasome regulator knockdown induced resistance to carfilzomib in MM and non-MM cells. 19S subunit knockdown did not affect the activity of the 20S subunits targeted by carfilzomib nor their inhibition by the drug, suggesting an alternative mechanism, such as the selective accumulation of protective factors. In MM patients, lower 19S levels predicted a diminished response to carfilzomib-based therapies. Together, our findings suggest that an understanding of network rewiring can inform development of new combination therapies to overcome drug resistance.

Article and author information

Author details

  1. Diego Acosta-Alvear

    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  2. Min Y Cho

    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  3. Thomas Wild

    The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  4. Tonia J Buchholz

    Onyx Pharmaceuticals, Inc. an Amgen subsidiary, South San Francisco, United States
    Competing interests
    Tonia J Buchholz, is an employee of Onyx Pharmaceuticals, an Amgen subsidiary.
  5. Alana G Lerner

    Onyx Pharmaceuticals, Inc. an Amgen subsidiary, South San Francisco, United States
    Competing interests
    Alana G Lerner, is an employee of Onyx Pharmaceuticals, an Amgen subsidiary.
  6. Olga Simakova

    Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  7. Jamie Hahn

    Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  8. Neha Korde

    Multiple Myeloma Section, Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, United States
    Competing interests
    No competing interests declared.
  9. Ola Landgren

    Multiple Myeloma Section, Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, United States
    Competing interests
    No competing interests declared.
  10. Irina Maric

    Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.
  11. Chunaram Choudhary

    The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark
    Competing interests
    No competing interests declared.
  12. Peter Walter

    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  13. Jonathan S Weissman

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    For correspondence
    Jonathan.Weissman@ucsf.edu
    Competing interests
    No competing interests declared.
  14. Martin Kampmann

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

Reviewing Editor

  1. Raymond J Deshaies, Howard Hughes Medical Institute, California Institute of Technology, United States

Ethics

Human subjects: The registered clinical research trial (NCT01402284) was approved by the National Cancer Institute (NCI) Institutional Review Board (IRB) and complied with the Declaration of Helsinki, the International Conference on Harmonization, and the Guidelines for Good Clinical Practice. All enrolled patients meeting criteria were consented with an IRB-approved document

Version history

  1. Received: April 16, 2015
  2. Accepted: August 31, 2015
  3. Accepted Manuscript published: September 1, 2015 (version 1)
  4. Version of Record published: October 19, 2015 (version 2)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 4,385
    Page views
  • 1,015
    Downloads
  • 67
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Diego Acosta-Alvear
  2. Min Y Cho
  3. Thomas Wild
  4. Tonia J Buchholz
  5. Alana G Lerner
  6. Olga Simakova
  7. Jamie Hahn
  8. Neha Korde
  9. Ola Landgren
  10. Irina Maric
  11. Chunaram Choudhary
  12. Peter Walter
  13. Jonathan S Weissman
  14. Martin Kampmann
(2015)
Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
eLife 4:e08153.
https://doi.org/10.7554/eLife.08153

Share this article

https://doi.org/10.7554/eLife.08153

Further reading

    1. Cell Biology
    2. Neuroscience
    Zhenyong Wu, Grant F Kusick ... Shigeki Watanabe
    Research Article

    Despite decades of intense study, the molecular basis of asynchronous neurotransmitter release remains enigmatic. Synaptotagmin (syt) 7 and Doc2 have both been proposed as Ca2+ sensors that trigger this mode of exocytosis, but conflicting findings have led to controversy. Here, we demonstrate that at excitatory mouse hippocampal synapses, Doc2α is the major Ca2+ sensor for asynchronous release, while syt7 supports this process through activity-dependent docking of synaptic vesicles. In synapses lacking Doc2α, asynchronous release after single action potentials is strongly reduced, while deleting syt7 has no effect. However, in the absence of syt7, docked vesicles cannot be replenished on millisecond timescales. Consequently, both synchronous and asynchronous release depress from the second pulse onward during repetitive activity. By contrast, synapses lacking Doc2α have normal activity-dependent docking, but continue to exhibit decreased asynchronous release after multiple stimuli. Moreover, disruption of both Ca2+ sensors is non-additive. These findings result in a new model whereby syt7 drives activity-dependent docking, thus providing synaptic vesicles for synchronous (syt1) and asynchronous (Doc2 and other unidentified sensors) release during ongoing transmission.

    1. Cell Biology
    Kazuki Hanaoka, Kensuke Nishikawa ... Kouichi Funato
    Research Article

    Membrane contact sites (MCSs) are junctures that perform important roles including coordinating lipid metabolism. Previous studies have indicated that vacuolar fission/fusion processes are coupled with modifications in the membrane lipid composition. However, it has been still unclear whether MCS-mediated lipid metabolism controls the vacuolar morphology. Here, we report that deletion of tricalbins (Tcb1, Tcb2, and Tcb3), tethering proteins at endoplasmic reticulum (ER)–plasma membrane (PM) and ER–Golgi contact sites, alters fusion/fission dynamics and causes vacuolar fragmentation in the yeast Saccharomyces cerevisiae. In addition, we show that the sphingolipid precursor phytosphingosine (PHS) accumulates in tricalbin-deleted cells, triggering the vacuolar division. Detachment of the nucleus–vacuole junction (NVJ), an important contact site between the vacuole and the perinuclear ER, restored vacuolar morphology in both cells subjected to high exogenous PHS and Tcb3-deleted cells, supporting that PHS transport across the NVJ induces vacuole division. Thus, our results suggest that vacuolar morphology is maintained by MCSs through the metabolism of sphingolipids.